population health

The Changing Landscape of Mortality in Diabetes: A Shift from Cardiovascular Dominance to Cancer and Dementia

By MedXY 03/14/2026

This review analyzes multinational data showing a significant decline in cardiovascular mortality among diabetes patients, alongside a concerning rise in dementia-related deaths and the emergence of cancer as a leading cause of mortality in high-income settings.

Cardiology news Public Health

Cardiovascular Risk Scores Overestimate Mortality in Mexican Adults: The Urgent Need for Population-Specific Recalibration

By MedXY 03/04/2026

A prospective study of over 112,000 adults in Mexico City reveals that standard CVD risk scores consistently overestimate 10-year fatal risk. Recalibration of the Globorisk-fatal model significantly improves predictive accuracy, highlighting the need for population-specific tools in clinical practice.

Cardiology Diabetes & Endocrinology news

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths

By MedXY 12/20/2025

This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate and unchanging excess risk over the last two decades.

Cardiology news

Unlocking Echocardiograms to Treat Undiagnosed Hypertension — The NOTIFY‑LVH Randomized Trial

By MedXY 12/03/2025

A centralized notification and support pathway using prior echocardiographic LVH increased antihypertensive initiation and new hypertension diagnoses versus usual care in a pragmatic randomized trial.

Clinical Updates Gastroenterology Oncology Public Health Specialties

Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial

By MedXY 09/13/2025

A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engaging younger populations in screening programs.